ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Christopher Taylor - VP, IR David Mauney - President Laurence Cooper - Chief Executive Officer Satyavrat Shukla - EVP and Chief Financial Officer Drew Deniger - Director of TCR Program Conference Call Participants David Novak - Raymond James Thomas Flaten - Lake Street Capital I-Eh Jen - Laidlaw Sean Lee - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the Ziopha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33038 ZIOPHARM Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1475642 (State or other jurisdiction of incorpor ...

1 Ziopharm o n c o l o g y Jefferies 2019 Global Healthcare Conference June 6, 2019 Forward Looking Statement 2 This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "coul ...

ZIOPHARM Oncology, Inc. (ZIOP) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Christopher Taylor - VP, IR David Mauney - President Laurence Cooper - CEO & Director Conference Call Participants Reni Benjamin - Raymond James & Associates Eric Joseph - JPMorgan Chase & Co. Swayampakula Ramakanth - H.C. Wainwright & Co. I-Eh Jen - Laidlaw & Company Thomas Flaten - Lake Street Capital Markets Operator Good afternoon, ladies and gentlemen, and welcome to the Ziopharm Oncology First Q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33038 ZIOPHARM Oncology, Inc. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification No.) One First Avenue, Parr ...

ZIOPHARM Oncology, Inc. (ZIOP) Q4 2018 Earnings Conference Call March 5, 2019 4:30 PM ET Company Participants David Connolly - IR Laurence Cooper - CEO David Mauney - President Conference Call Participants Reni Benjamin - Raymond James Eric Joseph - J.P. Morgan Sean Lee - H. C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Ziopharm Fourth Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and ins ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33038 ZIOPHARM Oncology, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 84-1475642 (State or Other Jurisdiction of Inc ...